Logo
    Search

    The Lancet Oncology in conversation with

    Editors at The Lancet Oncology, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy. 

    A monthly audio companion to the journal, this podcast covers a broad range of topics, from early-stage breast cancer treatment to mRNA vaccines, the access to essential cancer medicines for children to measuring ovarian toxicity, and more.

    enThe Lancet Group194 Episodes

    Episodes (194)

    Maria Kyrgiou on innovations in gynaecological cancers and global disparities

    Maria Kyrgiou on innovations in gynaecological cancers and global disparities

    In a special episode on International Women's Day 2024, we speak with Dr Maria Kyrgiou (Imperial College London, London, UK) about her Essay on innovations and disparities in gynaecological cancer care.

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    Georgios Lyratzopoulos on the use of chemotherapy and radiotherapy in patients with eight common cancers

    Georgios Lyratzopoulos on the use of chemotherapy and radiotherapy in patients with eight common cancers

    Dr Georgios Lyratzopoulos (University College London, London, UK) discusses his two papers from the International Cancer Benchmarking Partnership on the use of chemotherapy or radiotherapy in eight common cancers in Norway, the UK, Canada, and Australia.

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    Mike Sathekge on radioligand therapy of metastatic castration-resistant prostate cancer

    Mike Sathekge on radioligand therapy of metastatic castration-resistant prostate cancer

    Professor Mike Sathekge (Department of Nuclear Medicine, University of Pretoria, Pretoria, South Africa) discusses his Article entitled, ‘Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre retrospective study.’

    Read the full article:
    https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00638-1/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    Shankar Siva on stereotactic body radiotherapy for primary renal cell carcinoma

    Shankar Siva on stereotactic body radiotherapy for primary renal cell carcinoma

    Senior Editor Owen Stretton talks to Professor Shankar Siva from the Peter MacCallum Cancer Centre in Melbourne about the International Society of Stereotactic Radiosurgery’s new systematic review and practice guidelines for stereotactic body radiotherapy in primary renal cell carcinoma.

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    Neerja Bhatla on a new quadrivalent HPV vaccine

    Neerja Bhatla on a new quadrivalent HPV vaccine

    Professor Neerja Bhatla (All India Institute of Medical Sciences, New Delhi, India) discusses her Article on the Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9–14 years versus an established quadrivalent HPV vaccine in women aged 15–26 years in India.

    Read the full article:
    https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00480-1/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    Chandra Are on the Lancet Oncology Commission on Global Cancer Surgery

    Chandra Are on the Lancet Oncology Commission on Global Cancer Surgery

    Dr Chandra Are (University of Nebraska Medical Center, Omaha, NE, USA) discusses highlights and recommendations from the Lancet Oncology Commission on Global cancer surgery: pragmatic solutions to improve cancer surgery outcomes worldwide.

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    Philipp Karschnia on tissue sampling and processing during resection of diffuse intracranial glioma

    Philipp Karschnia on tissue sampling and processing during resection of diffuse intracranial glioma

    Doctor Philipp Karschnia (Ludwig-Maximilians-University of Munich, Munich, Germany) discusses the Response Assessment in Neuro Oncology consortium’s recommendations on standardised tissue sampling and processing during resection of diffuse intracranial glioma.

    Read the full Policy Review:
    https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00453-9/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    Wanda Cui on measuring ovarian toxicity

    Wanda Cui on measuring ovarian toxicity

    Dr. Wanda Cui (Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia) discusses her Review on measuring ovarian toxicity in clinical trials.

    Read the full article:
    https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00390-X/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    Ticiana Leal on Tumour Treating Fields

    Xuesong Han on cancer diagnosis during the COVID-19 pandemic in the USA

    Xuesong Han on cancer diagnosis during the COVID-19 pandemic in the USA

    Xuesong Han (American Cancer Society, Atlanta, GA, USA) discusses her study on changes in cancer diagnoses and stage distribution during the first year of the COVID-19 pandemic in the USA.

    Read the full article:
    https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00293-0/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    Carlos Fernández de Larrea and Damian Green on BCMA CAR T cells in multiple myeloma

    Carlos Fernández de Larrea and Damian Green on BCMA CAR T cells in multiple myeloma

    Carlos Fernández de Larrea (Hospital Clínic de Barcelona, Barcelona, Spain) and Damian Green (Fred Hutch Cancer Center, Seattle, WA, USA) discuss their studies on BCMA CAR T cells in patients with relapsed or refractory multiple myeloma.

    Read the full article:
    https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00246-2/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    Madeline Pe on the SISAQOL initiative

    Madeline Pe on the SISAQOL initiative

    Madeline Pe (EORTC, Brussels, Belgium) discusses her Policy Review on the innovative medicines initiative, an expansion of the Setting International Standards in Analysing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials (SISAQOL) initiative.

    Read the full article:
    https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00157-2/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    Kadia Petricca and Joyce Kambugu on access to essential cancer medicines for children

    Kadia Petricca and Joyce Kambugu on access to essential cancer medicines for children

    Dr Kadia Petricca (SickKids Hospital, Toronto, Canada), Dr Joyce Kambugu (Uganda Cancer Institute, Kampala, Uganda), and Dr Avi Denburg (SickKids Hospital) discuss their paper “Access to essential cancer medicines for children: a comparative mixed-methods analysis of availability, price, and health-system determinants in east Africa”.

    Read the full article:
    https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00072-4/fulltext?dgcid=buzzsprout_icw_podcast_lanonc_lancet

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    Mark Lythgoe on UK oncology drug approval after Brexit

    Mark Lythgoe on UK oncology drug approval after Brexit

    Dr Mark Lythgoe (Imperial College London, London, UK), discusses his new Review, "From The European Medicines Agency to Project Orbis: New activities and challenges to facilitate UK Oncology Drug Approval following Brexit".

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    Janet Brown on the phase 2/3 STAR trial

    Janet Brown on the phase 2/3 STAR trial

    Prof Janet Brown (University of Sheffield, Sheffield, UK) discusses the phase 2/3 STAR trial on treatment cessation versus continuation with tyrosine kinase inhibitors in advanced renal cell carcinoma.

    Read the full article:
    Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR)

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    Valerie Speirs on biomarkers in male breast cancer

    Valerie Speirs on biomarkers in male breast cancer

    Prof Valerie Speirs (University of Aberdeen, Aberdeen, Scotland) discusses her Systematic Review on genomic, transcriptomic, proteomic, epigenetic, and phenotypic biomarkers in male breast cancer.

    Read the full article:
    Defining genomic, transcriptomic, proteomic, epigenetic, and phenotypic biomarkers with prognostic capability in male breast cancer

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    Sameer Bakhshi on sex disparities in childhood cancer in India

    Sameer Bakhshi on sex disparities in childhood cancer in India

    Prof Sameer Bakhshi, (All India Institute of Medical Sciences, New Delhi, India) discusses his Article on sex disparities in childhood cancer in India.

    Read the full article:
    Sex disparity in childhood cancer in India: a multi-centre, individual patient data analysis

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    Shankar Siva on radiotherapy for primary renal cell carcinoma

    Shankar Siva on radiotherapy for primary renal cell carcinoma

    Shankar Siva (Peter MacCallum Cancer Centre, Melbourne, Australia) discusses his Article on 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma.

    Read the full article:
    5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    Mark Lawler and Richard Sullivan on the European Groundshot

    Mark Lawler and Richard Sullivan on the European Groundshot

    Mark Lawler (Queen’s University Belfast, Belfast, UK) and Richard Sullivan (Kings College London, London, UK) discuss the European Groundshot—addressing Europe’s cancer research challenges: a Lancet Oncology Commission.

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    Samar Alhomoud on challenges for cancer control in the Gulf region

    Samar Alhomoud on challenges for cancer control in the Gulf region

    Samar Alhomoud (King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia) discusses her review on progress and remaining challenges for cancer control in the Gulf Cooperation Council.

    Read the full article:
    Progress and remaining challenges for cancer control in the Gulf Cooperation Council

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv